Adapting to Progress: Axitinib Intravitreal Implant for Wet AMD

Adapting to Progress Axitinib Intravitreal Implant for Wet AMD
Media formats available:
Details
Presenters
  • Overview

    Dr. Eichenbaum will discuss the bioresorbable, hydrogel axitinib intravitreal implant that is under investigation in the SOL-1 phase 3 trial for the treatment of neovascular age-related macular degeneration.

    This activity is supported by an independent medical education grant from Ocular Therapeutix.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review key changes to trial design considerations that could stem from the FDA’s draft guidance for investigational therapies for nAMD
    • Explain the rationale for recent changes to clinical trial designs in nAMD
    • Summarize investigational therapies for nAMD that are in late phase clinical development
    • Evaluate how trial design choices for investigational therapies impact the interpretation of trial data and subsequent clinical decision-making
  • Accreditation

     Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Participation Method

    In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

  • Faculty and Disclosures

    David Eichenbaum, MD

    David Eichenbaum, MD

    Director of Research
    Retina Vitreous Associates of Florida
    Collaborative Associate Professor
    Morsani College of Medicine
    University of South Florida
    Tampa, FL

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    David Eichenbaum, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Amaros Medical, Annexon, Apellis Pharmaceuticals, Astellas, Bausch + Lomb, Coherus Biosciences, CorEvitas/Vestrum, Crinetics, EyePoint Pharmaceuticals, Genentech, Kodiak Sciences, Novartis, Ocular Therapeutix, Ocuphire, Opthea, Outlook, RecensMedical, Regeneron, Regenxbio, ReVive, Roche, and Samsara. Grant/Research Support: 4DMT, Aerie Pharmaceuticals, Alexion, Allegenesis Biotherapeutics, Annexon Biosciences, Astellas, Aviceda, Bayer, EyeBio, EyePoint Pharmaceuticals, Gemini Pharmaceuticals, Genentech, Gyroscope Therapeutics, Ionis Pharmaceuticals, Janssen, Kodiak Sciences, Kyowa Kirin, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, OcuTerra, ONL Therapeutics, Opthea, RecensMedical, Regeneron, Regenxbio, Roche, and Unity Biothechnology. Stock/Shareholder: Amaros Medical, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina. Speaker's Bureau: Alimera Sciences, Allergan, Apellis Pharmaceuticals, Astellas, Bayer, EyePoint Pharmacuticals, Genentech, Iveric Bio, and Regeneron.

    The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free